BIOR vs. DMTK, CNTG, XGN, RNLX, ENZ, MRNS, ASMB, SCYX, MIST, and ONCY
Should you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include DermTech (DMTK), Centogene (CNTG), Exagen (XGN), Renalytix (RNLX), Enzo Biochem (ENZ), Marinus Pharmaceuticals (MRNS), Assembly Biosciences (ASMB), SCYNEXIS (SCYX), Milestone Pharmaceuticals (MIST), and Oncolytics Biotech (ONCY).
DermTech (NASDAQ:DMTK) and Biora Therapeutics (NASDAQ:BIOR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership.
DermTech has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.
DermTech has higher revenue and earnings than Biora Therapeutics. DermTech is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks.
20.5% of DermTech shares are held by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are held by institutional investors. 5.1% of DermTech shares are held by company insiders. Comparatively, 51.0% of Biora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, DermTech and DermTech both had 2 articles in the media. Biora Therapeutics' average media sentiment score of 1.19 beat DermTech's score of 1.18 indicating that DermTech is being referred to more favorably in the media.
DermTech received 41 more outperform votes than Biora Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Biora Therapeutics an outperform vote while only 57.50% of users gave DermTech an outperform vote.
Biora Therapeutics has a net margin of 0.00% compared to Biora Therapeutics' net margin of -572.19%. DermTech's return on equity of 0.00% beat Biora Therapeutics' return on equity.
DermTech currently has a consensus price target of $2.38, suggesting a potential upside of 653.54%. Biora Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 2,244.48%. Given DermTech's stronger consensus rating and higher probable upside, analysts plainly believe Biora Therapeutics is more favorable than DermTech.
Summary
Biora Therapeutics beats DermTech on 9 of the 16 factors compared between the two stocks.
Get Biora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biora Therapeutics Competitors List
Related Companies and Tools
